Skip to Content
Menu
About
Science
EDO Platform
Scientific Publications
Pipeline
Overview
Clinical Trials
Expanded Access Policy
Community
Careers
Investors
News
Contact
Development of PGN-EDODM1, a Novel Enhanced Delivery Oligonucleotide that Targets the Root Cause of Myotonic Dystrophy Type 1
Post navigation
Previous:
The Use of the Enhanced Delivery Oligonucleotide (EDO) Platform to Develop a Treatment of myotonic dystrophy 1 (DM1)- an Update on the FREEDOM Clinical Study
Next:
FREEDOM-DM1: Final Results from a Phase 1, Placebo-controlled SAD Study to Evaluate PGN-EDODM1 in People with Myotonic Dystrophy Type 1 (DM1)
